Horton International (UK), today launched its 2017 European Life Science Report, published following Horton’s annual survey amongst the movers and shakers within the European Life Science sector.

The main findings in this year’s survey are as follows:

  • There is a belief that investment into the sector is likely to remain healthy, and potentially grow, over the coming 12 months.
  • Investors will be looking for new opportunities, as well as managing their existing portfolios.
  • IPOs will continue to be a viable route for companies to raise money in the coming year.
  • There is a general feeling that achieving an exit will prove to be no easier or no more difficult than in previous years.
  • There has been a continuing shift back to therapeutic proteins, with areas such as immune-oncology remaining one of the hot areas.  The other area creating interest is around personalised medicine and digital health.
  • It is felt that there will be a continued increase in employment in the sector.
  • There is a general consensus that the European Life Sciences sector is robust and, notwithstanding a global crisis such as a financial crash, will continue to offer good returns for investors.

For a copy of the full report, please contact Paul Edwards at edwards@horton-intl.co.uk

Paul Edwards is the Managing Partner, Global Healthcare with Horton International, a leader in the Executive Search community.